Search Results

Genetic editing shows promise in Duchenne muscular dystrophy

June 4, 2013 Using a novel genetic 'editing' technique, Duke University biomedical engineers have been able to repair a defect responsible for one of the most common inherited disorders, Duchenne muscular dystrophy, in cell samples from Duchenne patients.

Duke Researchers Garner Over $6 Million in NIH Funding to Fight Genetic Diseases – Duke Today

Hemophilia. Cystic fibrosis.

Duke researchers land $6M in federal grants to advance gene editing – WRAL Tech Wire

DURHAM Hemophilia. Cystic fibrosis.

Gene Therapy Initiative – gilbertfamilyfoundation.org

Exploring Nonsense Suppressionas a Treatment for NF1 This project aims to find compounds that suppress the effects of nonsense mutations in the NF1 gene, thus restoring neurofibromin protein expression and function in NF1 patients. David Bedwell, PhDUniversity of Alabama, Birmingham Bruce Korf, MD, PhDUniversity of Alabama, Brimingham Mark Suto, PhDSouthern Research This project will resolve two primary challenges applying gene therapy approaches to NF1 by using an innovative strategy to engineer new viruses that targets tumor initiating cells and CRISPR-based genome editing to restore the mutated NF1 gene.

Statement: New MDA-Funded Genetic Therapy Technique Targets DMD

Chicago, IL (PRWEB) February 27, 2015 Muscular Dystrophy Association research grantee Charles Gersbach, Assistant Professor of Biomedical Engineering at Duke University, recently announced a potentially game-changing advance in gene modification for boys and young men with Duchenne muscular dystrophy (DMD). The results were published Feb. 18 in Nature Communications, and Gersbach will discuss their implications at MDA's 2015 Scientific Conference, to be held March 11-14 in Washington, D.C.

Duke Signs Exclusive Licensing Agreement with Leading Genome Editing Company

Duke University has signed an exclusive licensing agreement with Editas Medicine, a leading genome editing company, for genetic engineering technologies developed in the lab of Charles Gersbach, assistant professor of biomedical engineering. The agreement focuses on Gersbachs work with genome engineering technologies known as CRISPR/Cas9 and TALENs. Charles Gersbach The agreement allows broad use of the technology developed in Gersbachs lab for the prevention or treatment of human disease

Archives
-->